Jan 24, 2025

These workflows will utilise Merck’s extensive range of automation-enabled assays. Combining the workstation and assays will enhance consistency and throughput while minimising manual intervention. The user-friendly robotic system will be a significant step towards minimising recurring tasks in the laboratory. Customers can order custom workstations and assay kits from Merck later this year. The applications of these products will span a wide range of laboratory procedures, including the preparation of protein samples and various chemistry and biochemical workflows. How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network. Submit and download Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Merck Life Science business, Science & Lab Solutions head Jean-Charles Wirth said: “Our customers are prioritising tools and technologies that improve reproducibility and productivity, allowing them to focus on more complex tasks that take their science further, faster. “Our partnership with Opentrons reinforces our focus to automate and digitalise the lab – supporting scientists at all stages with tools that can increase efficiency, safety, and success rates of delivering new potential therapeutics.” Merck noted that by leveraging Opentrons’ automation expertise with its supply chain, R&D and quality systems, this collaboration is set to provide products that streamline research workflows from sample preparation to analysis. This partnership will support advancements in areas such as enzyme technology, genome editing, immunodetection, pharmaceutical development, and testing services. It builds upon Merck’s ongoing efforts to enhance the productivity of its Life Science lab. Notable among these is the Millicell DCI Digital Cell Imager, which facilitates expedited cell culture analysis through its user-friendly interface. Additionally, this development underscores the company’s aim to deliver advanced biology solutions, such as its recent purchase of HUB Organoids. In July 2021, Merck partnered with Innervia Bioelectronics to develop graphene-based bioelectronic vagus nerve treatments for severe chronic conditions. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.